Arina Trial Research Kft. — Clinical Trial Site

16 Registered trials

4 Currently recruiting

Organisation

Arina Trial Research Kft.

Location

Oroshaza, Hungary

Identifier

ORG-100045929

Address

Kigyo Utca 24, 5900, Hungary

Departments

-
Belgyógyászati - Kardiológiai –Diabetológiai Magánrendelés
Cardiology
Dr Nagy Laszlo Kardiologiai maganrendeles es SMO
Dr. Nagy László Kardiológiai magánrendelés és SMO
N/A
NA
Not applicable
Private Practice

Clinical trials at this site (16)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit… Ended

2023-509066-38-00 Atrial Fibrillation 4 2021-04-16
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti… Ended

2023-508737-13-00 chronic heart failure 4 2024-08-08
A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended

2023-506197-12-00 Dyslipidemia Dyslipidemias are alterations to the plasm 4 2024-02-07
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Obesity 5 2024-01-18
Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I… Ended

2023-507569-24-00 Myocardial Infarction, Acute Heart Failure, Left Sided 4 2022-06-20